Cancers (Sep 2019)

TREM2 Acts as a Tumor Suppressor in Colorectal Carcinoma through Wnt1/<i>β</i>-catenin and Erk Signaling

  • Su-Man Kim,
  • Eun-Mi Kim,
  • Kon-Young Ji,
  • Hwa-Youn Lee,
  • Su-Min Yee,
  • Su-Min Woo,
  • Ja-Woon Yi,
  • Chul-Ho Yun,
  • Harim Choi,
  • Hyung-Sik Kang

DOI
https://doi.org/10.3390/cancers11091315
Journal volume & issue
Vol. 11, no. 9
p. 1315

Abstract

Read online

TREM2 (triggering receptor expressed on myeloid cells) is involved in the development of malignancies. However, the function of TREM2 in colorectal cancer has not been clearly elucidated. Here, we investigated TREM2 function for the first time in colorectal epithelial cancer cells and demonstrated that TREM2 is a novel tumor suppressor in colorectal carcinoma. Blockade of TREM2 significantly promoted the proliferation of HT29 colorectal carcinoma cells by regulating cell cycle-related factors, such as p53 phosphorylation and p21 and cyclin D1 protein levels. HT29 cell migration was also increased by TREM2 inhibition via MMP9 (matrix metalloproteinase 9) expression upregulation. Furthermore, we found that the tumor suppressor effects of TREM2 were associated with Wnt/β-catenin and extracellular signal-regulated kinase (ERK) signaling. Importantly, the effect of TREM2 in the suppression of tumor development was demonstrated by in vivo and in vitro assays, as well as in human colon cancer patient tissue arrays. Overall, our results identify TREM2 as a potential prognostic biomarker and therapeutic target for colorectal cancer.

Keywords